Arzerra Fails in Late-stage Trial
the Cancer Therapy Advisor take:
On June 27, GlaxoSmithKline Plc and Genmab A/S reported that Arzerra, their leukemia drug, failed a late-stage trial because the drug was not able to treat patients with bulky fludarabine-refractory chronic lymphocytic leukemia more effectively than other drugs.
Due to European regulations for conditional approval of the drug, the effects of Arzerra were examined in this patient population, which is chemically known as ofatumumab.
Although patients who were given Arzerra had 5.4 months before disease progression, which is higher than the 3.6 months reported for patients treated with the physician’s choice of alternative therapy, the difference is not statistically significant. The results of the study hindered the companies’ ability to apply for marketing of approval for Arzerra to treat patients with the aforementioned type of blood cancer.
However, Arzerra is approved to treat patients with newly diagnosed chronic lymphocytic leukemia. For this blood cancer, the chemotherapy fludarabine is an inappropriate treatment.
Arzerra Fails Late-stage Trial
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer